A Prospective Observational Study on Comparison of Safety and Efficacy of Nitrates And Nicorandil in Anginal Pain

2021 ◽  
Vol 11 (3) ◽  
pp. 2531-2537
Author(s):  
Sabitha Mary Kurian ◽  
Elizabeth Shaji ◽  
Arif B Siyad ◽  
Fabin Fabin M ◽  
Vinod Thomas
Keyword(s):  
Observational Study ◽  
Prospective Observational Study ◽  
Safety And Efficacy ◽  
Anginal Pain

scholarly journals Safety and Efficacy of Mobility Interventions in Patients with Femoral Catheters in the ICU: A Prospective Observational Study

2013 ◽  
Vol 24 (2) ◽  
pp. 12-17 ◽  
Author(s):  
Christiane Perme ◽  
Theresa Nalty ◽  
Chris Winkelman ◽  
Ricardo Kenji Nawa ◽  
Faisal Masud
Keyword(s):  
Observational Study ◽  
Prospective Observational Study ◽  
Safety And Efficacy

scholarly journals Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

2020 ◽  
Vol 7 (9) ◽  
pp. 1428-1436 ◽  
Author(s):  
Mingxing Huang ◽  
Man Li ◽  
Fei Xiao ◽  
Pengfei Pang ◽  
Jiabi Liang ◽  
...  
Keyword(s):  
Adverse Events ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Viral Rna ◽  
Absolute Difference ◽  
Safety And Efficacy ◽  
Full Dose ◽  
Half Dose ◽  
Multicenter Prospective Observational Study ◽  
Historical Controls

Abstract Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19. In this multicenter prospective observational study, we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces. Eligible patients received chloroquine phosphate 500 mg, orally, once (half dose) or twice (full dose) daily. Patients treated with non-chloroquine therapy were included as historical controls. The primary endpoint is the time to undetectable viral RNA. Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14, hospitalization time, duration of fever, and adverse events. A total of 197 patients completed chloroquine treatment, and 176 patients were included as historical controls. The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians −6.0 days; 95% CI −6.0 to −4.0). The duration of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8). No serious adverse events were observed in the chloroquine group. Patients treated with half dose experienced lower rate of adverse events than with full dose. Although randomized trials are needed for further evaluation, this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic.

Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study

2016 ◽  
Vol 203 ◽  
pp. 167-172 ◽  
Author(s):  
Helena Kopp Kallner ◽  
Anna Almén Christensson ◽  
Caroline Elmér ◽  
Benjamin Flam ◽  
Daniel Altman
Keyword(s):  
Clinical Practice ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Daily Clinical Practice ◽  
Safety And Efficacy
Sign in / Sign up

Export Citation Format

Share Document